Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in epicardial cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.40 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 52 | 0.76 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3052
Sealed predictions
- LRRN3 in dopamine neurons, braak+0.12 (p 0.768) → -0.34 (p 0.373)receipt 3059
Swarm cases
receipt 3059: LRRN3 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.337, n 18), 95% CI -0.64 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.337, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.250, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.13, sign flips 0; without severely affected donors -0.24 (p 0.337, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LRRN3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts